NCT04553133 2025-08-28PF-07104091 as a Single Agent and in Combination TherapyPfizerPhase 2 Active not recruiting154 enrolled
NCT01655225 2022-04-08A Study of LY3023414 in Participants With Advanced CancerEli Lilly and CompanyPhase 1 Completed156 enrolled